17,261 trials
Diffuse Lewy Body Disease · Dementia With Lewy Bodies · Parkinson's Disease Dementia
Primary: Absolute 11C-PBR28 Binding (Total Distribution Volume Corrected for Free Fraction in Plasma) — 0.15 kBq·cm-3 / kBq·mL-1
Urothelial Carcinoma · Bladder Cancer
Primary: Phase Ib: Safety of Pembrolizumab in Combination With Gemcitabine-Cisplatin — 0 Participants
Panic Disorder
Primary: Incidence of Treatment-Emergent Adverse Events — 23; 15 Participants
Plasma Cell Leukemia · Plasmacytoma · Recurrent Plasma Cell Myeloma
Primary: Progression Free Survival (PFS) — 38; 24 Participants
Advanced Solid Cancers · Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies
Primary: Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) of Zalifrelimab — 0; 0; 0; 0 Participants
Advanced Solid Tumours
Primary: Monotherapy (Modules 1 and 2): Progression Free Survival Rate at 6 Months — NA; 6.1 percentage of participants
Small Cell Carcinoma · Carcinoma, Non-Small-Cell Lung · Neuroendocrine Tumors
Primary: Overall Survival — 6.85; 7.6; 7.5 Months
Dyslipidemias · Lipid Metabolism Disorders · Metabolic Diseases
Primary: Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180 — -11.6; -14.1; -24.3; -19.0 Percent change — p=0.691
Chronic Kidney Disease-associated Pruritus
Primary: Mean Change in Weekly Mean Worst Itch Numeric Rating Score (WI-NRS) — -3.70; -3.87 score on a scale
Solid Tumor, Adult · Advanced Solid Tumor · Metastatic Solid Tumor
Primary: Objective Response Rate (ORR) as Assessed Based on Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1) — 20.0; 0; 37.5; 0 percentage of participants
Immune Thrombocytopenia (ITP)
Primary: Percentage of Patients With Sustained Response Off Treatment at 52 Weeks — 2; 2 Participants — p=0.5133
Aging
Primary: Neurovascular Coupling — 0.68; 0.26; 0.80 cm/s
Acromegaly
Primary: Responder Criteria Was Based on the Mean of Two Consecutive Insulin-like Growth Factor-1 [IGF-1] Measurements ≤ULN at Week 13 — 66.7; 25.0; 16.7 percentage of responders
Breast Cancer · Metastatic Breast Cancer · BRCA1 Gene Mutation
Primary: Objective Response Rate (ORR) of ABT-888 and Temozolomide (TMZ) in Metastatic Breast Cancer — 4; 3 Participants
Histoplasmosis · AIDS
Primary: Clinical Response — 32; 25; 28 Participants